Central Garden & Pet just delivered its best quarterly result on record — and the market went cold on it almost immediately.
The company reported Q2 fiscal 2026 adjusted EPS of $1.29, well clear of the $1.10 consensus estimate. Revenue of $906M topped the $844M forecast by a wide margin. Those are genuine beats. Then came the full-year guidance: management guided FY2026 EPS to more than $2.70, against a Street estimate of $2.85. The number was enough to wipe out much of the post-print enthusiasm. That tension — record top-line quarter, trimmed annual outlook — frames the setup heading into the back half of the year.
The borrow market is not adding pressure here. Short interest has eased all week, falling about 4.6% over five days to 3.5% of the free float. That's a modest level for a small-cap household products name. Cost to borrow has also come off, now running near 0.58% — down roughly 6% on the week and 14% over the past month. Borrow availability is extremely loose at 835% of short interest, meaning there are more than eight shares available to lend for every one currently borrowed. None of this suggests short sellers are pressing a thesis into earnings. If anything, the short-side unwind has accelerated into the print.
Options positioning is similarly relaxed. The put/call ratio is 0.35, almost exactly in line with its 20-day average of 0.34, giving a z-score near zero. That's consistent with a market that was not particularly hedged or directionally opinionated ahead of the report. The PCR has ranged from 0.13 to 1.17 over the past year — today's reading is firmly mid-range. Taken together, short interest and options were both telling the same quiet story going into earnings.
The Street's view is harder to read clearly. Analyst coverage appears sparse — the most recent target change was a Canaccord Genuity maintenance of its Buy rating and $50 target in late November 2025, and the data beyond that point is dated. What can be said is that the consensus has been constructively positioned. The mean target was $46.50, against a pre-print price near $36, implying roughly 29% upside on paper — though some of those targets stretch back to mid-2024 and may not reflect the guidance cut. The ORTEX short score has drifted lower all week, from 40.5 on April 24 to 39.8 by Wednesday, ranking in the 36th percentile of peers. Days to cover rank in just the 14th percentile. Neither signal suggests the stock is a crowded short.
On the ownership side, BlackRock recently reported a small addition, lifting its stake to 15.4% of shares outstanding. American Century added more aggressively — 422,000 shares in the most recent filing period. Insider activity is sparse and stale; the most recent trade in the dataset is a director sale in February 2025, too dated to carry weight now.
What to watch next is simple: how the stock digests the guidance cut in the days after the record Q2 beat. The gap between the EPS beat and the lowered annual forecast frames whether management's conservatism reads as credible caution or as an early warning — and the price action after the close on May 6 will be the first signal on which way the Street is leaning.
See the live data behind this article on ORTEX.
Open CENT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
